Danaher Corporation

NYSE:DHR

Medical - Diagnostics & Research

Healthcare
$228.41 -0.21%

-$0.38 today

Market cap
$160.69B
Beta
0.83
P/E (TTM)
34.0
EPS (TTM)
$5.21
Dividend yield
0.77%
52W Low $160.93High $242.80

Volume 2.92M

Average 4.52M

DHR Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Danaher CorporationNYSE: DHR

Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026

Depreciation & amortization outflow shrinks to $0

Q3 FY2026 depreciation & amortization was $0, compared with $622M a year earlier. Trailing-twelve-month depreciation & amortization was $1.91B. Over 3 fiscal years it compounded at +4.7% a year.

Context

  • Depreciation & amortization amounted to 10.0% of revenue in FY2025, up 0.1 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $477.25M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$2.45B+4.0% YoY
LTMSep 2026
$1.91B-21.1% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+4.0%——
3-year CAGR+4.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
2.45B USD
Year-over-year change
+4.0%
4-year CAGR
+3.1%

Depreciation & Amortization vs competitors

How DHR compares with its peers on the latest reported figures

  • DHR's LTM Sep 2026 depreciation & amortization of $1.91B is the 2nd largest of the 9 companies compared; the peer median is $272M.
  • Its year-over-year change of -21.1% is the lowest of 9, against a peer median of +7.2%.
  • Depreciation & amortization amounts to 7.5% of revenue for DHR, versus a peer median of 6.6%.
DHR Competitors Peer median
Depreciation & Amortization for DHR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TMOThermo Fisher Scientific Inc.LTM Sep 2026$3.11B +11.2%-6.3%6.6%
DHRDanaher CorporationLTM Sep 2026$1.91B -21.1%+4.7%7.5%
WATWaters CorporationLTM Jul 2026$613.22M +211.1%+16.5%13.2%
RVTYRevvity, Inc.LTM Jul 2026$412.24M -0.2%-1.7%14.2%
ILMNIllumina, Inc.LTM Jun 2026$273M -1.8%-11.8%6.1%
AAgilent Technologies, Inc.LTM Jul 2026$271M -5.2%-3.1%3.7%
BRKRBruker CorporationLTM Jun 2026$230.1M +9.4%+35.4%6.6%
QGENQiagen N.V.LTM Jun 2026$202.13M +7.0%-2.4%9.6%
MTDMettler-Toledo International Inc.LTM Jun 2026$131M +7.3%+3.6%3.2%
Peer median (excluding DHR) $272M+7.2%-2.1%6.6%

Competitors are the stored peer set for DHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income6.35B7.21B4.22B3.9B3.61B
Depreciation & Amortization2.17B2.13B2.17B2.35B2.45B
Deferred Income Tax(318M)(559M)00(440M)
Stock-Based Compensation184M295M306M288M298M
Change in Working Capital(658M)(1.52B)(393M)266M(710M)
Accounts Receivables(611M)(477M)322M331M(216M)
Inventory(502M)(486M)185M147M(58M)
Accounts Payables549M5M(149M)19M9M
Other Working Capital(94M)(561M)(751M)(231M)(445M)
Other Non-Cash Items601M961M864M(117M)1.21B
Operating Cash Flow8.36B8.52B7.16B6.69B6.42B
Capital Expenditures(1.29B)(1.15B)(1.38B)(1.39B)(1.16B)
Acquisitions (Net)(10.94B)(637M)(5.61B)(558M)9M
Purchases of Investments(934M)(523M)(172M)(331M)(127M)
Sales of Investments126M18M61M253M12M
Other Investing Activities50M60M23M47M66M
Investing Cash Flow(12.99B)(2.23B)(7.08B)(1.98B)(1.2B)
Debt Repayment1.97B(1.69B)(1.63B)(1.67B)1.05B
Common Stock Issued86M31M68M162M85M
Common Stock Repurchased000(5.98B)(3.09B)
Dividends Paid(742M)(818M)(821M)(768M)(878M)
Other Financing Activities(16M)(95M)2.11B(131M)(125M)
Financing Cash Flow1.3B(2.57B)(273M)(8.39B)(2.96B)
Effect of Forex Changes(115M)(306M)59M(108M)278M
Net Change in Cash(3.45B)3.41B(131M)(3.79B)2.54B
Free Cash Flow7.06B7.37B5.78B5.3B5.26B

Danaher Corporation

NYSE:DHR

Intrinsic Alpha fair value

Locked

Current Price

$228.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.